We are live on ! Find out more
SNOA icon

Sonoma Pharmaceuticals
SNOA

16 hedge funds and large institutions have $396K invested in Sonoma Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.01% less ownership

Funds ownership: 0.3% → 0.29% (-0.01%)

6% less funds holding

Funds holding: 17 → 16 (-1)

31% less capital invested

Capital invested by funds: $574K → $396K (-$178K)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
16
Holders Change
-1
Holders Change %
-5.88%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$14.1K
2
TRCT
Tower Research Capital (TRC)
New York
+$12.9K

Top Sellers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
-$21.6K
2
Citadel Advisors
Citadel Advisors
Florida
-$21.4K
3
Renaissance Technologies
Renaissance Technologies
New York
-$1.17K
4
HFS
HBC Financial Services
Washington
-$469

SNOA Hedge Fund Activity: Q3 2022 in Review

16 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Sonoma Pharmaceuticals (SNOA) for Q3 2022, worth a combined $396K — down 31% from $574K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of SNOA and 0 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.

The largest buyer was UBS Group, adding an estimated $14.1K. The largest seller was Bank of America, cutting an estimated $21.6K.

  • 16 institutional investors held Sonoma Pharmaceuticals (SNOA) as of Q3 2022, down from 17 in Q2 2022.
  • Funds reported $396K of Sonoma Pharmaceuticals stock for Q3 2022, down 31% quarter-over-quarter.
  • 0 funds opened new Sonoma Pharmaceuticals positions in Q3 2022 and 1 closed out, a net change of -1 holder.
  • The largest Sonoma Pharmaceuticals buyer in Q3 2022 was UBS Group, an estimated $14.1K added.
  • The largest Sonoma Pharmaceuticals seller in Q3 2022 was Bank of America, an estimated $21.6K sold.

Based on aggregated 13F filings for Q3 2022.